evidencegaps
Primary study · included by 1 review

Salivary gland toxicity after radioiodine therapy for thyroid cancer.

Hyer 2007 · Hyer S, Kong A, Pratt B, et al. · Clinical oncology (Royal College of Radiologists (Great Britain)) · 2007

Included by

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Non-Cochrane · prognostic · 2026 · cited as Hyer 2007 · Supplementary Table S3 (included studies); Figs. 1-3
Outcome this study informsPooled effectEvidenceCertainty
Sialadenitis (pooled prevalence)
Radioiodine (I131) therapy · between 6 months and 1 year after RIT
Prevalence 0.20 [0.12, 0.31]3 studies · 527 participantsGRADE not reported
Sialadenitis (pooled prevalence)
Radioiodine (I131) therapy · within 2 months after RIT
Prevalence 0.30 [0.12, 0.59]3 studies · 1563 participantsGRADE not reported
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · between 6 months and 1 year after RIT
Prevalence 0.19 [0.14, 0.25]5 studies · 885 participantsGRADE not reported
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · between 2 and 6 months after RIT
Prevalence 0.37 [0.28, 0.47]4 studies · 392 participantsGRADE not reported

1 including review in total.